Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authoridFatma Paksoy Türköz / 0000-0002-2314-263X
dc.authorscopusidFatma Paksoy Türköz / 36560519600
dc.authorwosidFatma Paksoy Türköz / ABF-9350-2020en_US
dc.contributor.authorTatlı , Ali Murat
dc.contributor.authorErdem, Dilek
dc.contributor.authorGöker, Erdem
dc.contributor.authorÇelik, Emir
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAtçı , Muhammed Mustafa
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorAkın Telli, Tuğba
dc.contributor.authorBilgin, Burak
dc.contributor.authorBilici, Ahmet
dc.contributor.authorAkangündüz , Baran
dc.contributor.authorBallı, Sevinç
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorÇavdar, Eyyüp
dc.contributor.authorÖztürk, Akın
dc.contributor.authorTürkmen Bekmez, Esma
dc.contributor.authorTurhal, Serdal
dc.contributor.authorKılıçkap, Sadettin
dc.contributor.authorYıldırım, Hasan Çağrı
dc.contributor.authorOyan, Başak
dc.contributor.authorAksoy, Asude
dc.contributor.authorPaksoy Türköz, Fatma
dc.contributor.authorKut, Engin
dc.contributor.authorKatgı, Nuran
dc.contributor.authorSakalar, Teoman
dc.contributor.authorAkyol, Murat
dc.contributor.authorEllez, Halil İbrahim
dc.contributor.authorTopçu, Atakan
dc.contributor.authorErdoğan, Atike Pınar
dc.contributor.authorPılancı, Kezban Nur
dc.contributor.authorHedem, Engin
dc.contributor.authorArak, Hacı
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorAlan, Özkan
dc.contributor.authorYapar, Burcu
dc.contributor.authorNart, Deniz
dc.contributor.authorYumuk, Perran Fulden
dc.date.accessioned2022-05-20T06:46:48Z
dc.date.available2022-05-20T06:46:48Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractObjectives To compare the survival of frst- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as frst line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p=0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p=0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically signifcant (p=0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically diferent than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p=0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both frst- and second-generation EGFR-TKIs should be considered, especially as frst- and second-line options.en_US
dc.identifier.citationGursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2022 Apr 5. doi: 10.1007/s00432-022-03984-5. Epub ahead of print. PMID: 35381885.en_US
dc.identifier.doi10.1007/s00432-022-03984-5en_US
dc.identifier.issn0171-5216en_US
dc.identifier.pmid35381885en_US
dc.identifier.scopus2-s2.0-85127494466en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1007/s00432-022-03984-5
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2672
dc.identifier.wosWOS:000779481900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorPaksoy Türköz, Fatma
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectExon 18en_US
dc.subjectExon 20en_US
dc.subjectErlotiniben_US
dc.subjectAfatiniben_US
dc.subjectNSCLCen_US
dc.titleReal-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Gursoy2022_Article_Real-lifeComparisonOfAfatinibA.pdf
Boyut:
1.05 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu